fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

LBL Invites the Public to Attend a Public Listening Session

KENTUCKY (6/1/15) — Land Between The Lakes National Recreation Area will hold a public listening session from 6 to 8:30… Read More

White Lightning Mountain Bike Race Takes Place June 7

KENTUCKY (5/31/15) — Endurance-Plus will sponsor the White Lightning mountain bike race Sunday, June 7, at Land Between… Read More

Most Read This Week

May 27, 2015 7425

VIDEO: Sparks Fly Over Hanson Rezoning Issue

by Tammy Holloway, SurfKY News
May 30, 2015 7143

Study of Virus Attack on Cancer Sees Success

by Julie Heflin
May 28, 2015 6549

Four Charged with Burglary for Entering Elderly…

by SurfKY News
May 27, 2015 4283

Midnight Ride on Rabbit Ridge Ends in Jail

by SurfKY News
May 27, 2015 3870

Crime Stoppers Top Most Wanted - May 27, 2015

by Crime Stoppers

Most Read This Month

May 15, 2015 11337

New Madisonville Business In Full Operation Soon

by Tammy Holloway, SurfKY News
May 23, 2015 9416

Missing 5-Year-Old Boy Found

by Doreen Dennis, SurfKY News

Stories Trending Now

June 01, 2015 1583

Authorities Discover Meth Lab While Assisting…

by SurfKY News
May 31, 2015 1569

Hopkins District Court Fines Handed Down

by SurfKY News
June 01, 2015 1333

Madisonville Police Arrest Reports Released -…

by SurfKY News
June 02, 2015 1261

Two Muhlenberg Women Injured in Collision

by SurfKY News
June 02, 2015 1251

Woman Charged with Falsely Reporting Kidnapping

by SurfKY News
May 31, 2015 1113

Survivors, Caregivers, Supporters Gather for…

by Tammy Holloway, SurfKY News
June 02, 2015 1101

Traffic Signal at Intersection in Downtown…

by Keith Todd
June 01, 2015 1097

Human Relations Coordinator Identifies Possible…

by Tammy Holloway, SurfKY News
June 02, 2015 1059

Juveniles Accused of Falsely Reporting Masked…

by Rita Dukes Smith, SurfKY News Director
June 02, 2015 1001

Hopkins County Misdemeanor Indictments

by SurfKY News